Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Press Release: Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand

Zymeworks Sees Current Cash Resources, Expected Payments to Support Operations Into H2 2027

Scholar Rock Plans Apitegromab Commercialization, Expanded Use in 2025

CareDx Updates Director Compensation and Vesting Policies

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?

Zymeworks Sets Strategic Milestones for 2025-2026 with Focus on Novel Therapeutics

Monthly information on share capital and company voting rights

Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

Vanda Pharmaceuticals: Issued Letter to FDA Regarding Sept. 18, 2024 Crl in Reference to Co's Nda for Tradipitant for Treatment of Gastroparesis

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis Nda Review

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

BRIEF-Adicet Bio Provides Corporate Update

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

BRIEF-Scholar Rock Highlights 2025 Strategic Priorities

Adicet Bio Inc - Patient Enrollment for Sle, Ssc, Iim, SPS Expected in 1Q25